# Rheumatology Live

> Rheumatology Live - Healthcare Publication

- Base URL: https://www.rheum-live.com
- Generated: 2026-09-10T03:00:56.788Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.rheum-live.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.rheum-live.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.rheum-live.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.rheum-live.com/robots.txt](https://www.rheum-live.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Clinical](https://www.rheum-live.com/clinical)
- [Conference](https://www.rheum-live.com/conference)
- [News](https://www.rheum-live.com/news)
- [Peer Exchange](https://www.rheum-live.com/peer-exchange)
- [Peers Perspectives](https://www.rheum-live.com/peers-perspectives)
- [Physician's Money Digest](https://www.rheum-live.com/physicians-money-digest)
- [Podcasts](https://www.rheum-live.com/podcasts)
- [Rheumatology](https://www.rheum-live.com/clinical)
- [Strategic Alliance Partnership](https://www.rheum-live.com/sap-partner)
- [Video Series](https://www.rheum-live.com/video-series)
- [Videos](https://www.rheum-live.com/videos)

## Featured Content

- [FDA Granted Certolizumab Pegol Breakthrough Status for APS in Pregnancy](https://www.rheum-live.com/view/certolizumab-pegol-fda-breakthrough-therapy-aps-pregnancy): The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.
- [High BMI Lowers Odds of Achieving MDA in PsA on TNFi](https://www.rheum-live.com/view/high-bmi-lowers-odds-of-achieving-mda-in-psa-on-tnfi): In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
- [5 Headlines You Missed in August 2026](https://www.rheum-live.com/view/5-pulmonology-headlines-you-missed-in-august-2026): August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
- [Joint Ventures: Unpacking the History and Modern Use of Steroids in Rheumatology](https://www.rheum-live.com/view/joint-ventures-unpacking-the-history-and-modern-use-of-steroids-in-rheumatology): Hosts Buss and Arnold trace glucocorticoids from their 1948 discovery to today's steroid-sparing dilemmas in RA and lupus.
- [Model Predicts Persistent Arthritis After Checkpoint Inhibitor Therapy](https://www.rheum-live.com/view/model-predicts-persistent-arthritis-checkpoint-inhibitor-therapy): Kate Harnden, MBChB, discusses new study that identifies factors tied to disease persistence in patients with immune checkpoint inhibitor-induced arth...
- [Ethnicity Drives Unequal Steroid Use in Lupus, With Sarah Dyball, PhD](https://www.rheum-live.com/view/ethnicity-drives-unequal-steroid-use-lupus-sarah-dyball-phd): Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
- [FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients](https://www.rheum-live.com/view/fda-approves-first-oral-treatment-of-dermatomyositis-in-adult-patients): The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adul...
- [Trial Design Drives Radiographic Outcomes Across IL-23 Inhibitors in PsA](https://www.rheum-live.com/view/trial-design-radiographic-outcomes-across-il-23-inhibitors-psa): Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.
- [FDA Approves Garetosmab-grts for Fibrodysplasia Ossificans Progressiva ](https://www.rheum-live.com/view/fda-approves-garetosmab-grts-for-fibrodysplasia-ossificans-progressiva): Garetosmab-grts is the first treatment demonstrating reduced new heterotopic ossification lesions and flare-ups in adults with FOP.
- [ALKIVIA: Efgartigimod Improves Myositis, Hits Phase 3 Primary End Point](https://www.rheum-live.com/view/alkivia-efgartigimod-improves-myositis-hits-phase-3-primary-end-point): Efgartigimod produced significant, sustained improvement in autoimmune myositis, including the first positive phase 3 results in IMNM.

## Feeds and Indexes

- [RSS Feed](https://www.rheum-live.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.rheum-live.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.rheum-live.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.rheum-live.com/authors): Browse all contributors and their published work